Billing of botulinum toxin for hyperhidrosis: Ethical considerations.

J Am Acad Dermatol

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. Electronic address:

Published: April 2018

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2017.08.023DOI Listing

Publication Analysis

Top Keywords

billing botulinum
4
botulinum toxin
4
toxin hyperhidrosis
4
hyperhidrosis ethical
4
ethical considerations
4
billing
1
toxin
1
hyperhidrosis
1
ethical
1
considerations
1

Similar Publications

Introduction: The healthcare system in the United States relies heavily on physician-and house officer-driven initiation of billing and coding for collection of hospital payments and professional fees. Under the umbrella of practice management is the ever-changing and suboptimally taught concept of procedural billing and coding to house officers and faculty. Clinical providers and practitioners initiate billing and coding for performed services based on the procedural visit encounter, supported by the appropriate documentation.

View Article and Find Full Text PDF

Background: OnabotulinumtoxinA (Botox) has been approved in Germany since 2013 for the second-line treatment of idiopathic overactive bladder in the form of a detrusor injection (OnabotA DI) after failure of anticholinergic therapy. Until 2018, however, its application lagged far behind the demand due to billing hurdles. Since the beginning of 2018, there has been an EBM (German Uniform Evaluation Standard) approval number in Germany for the transurethral application of Botox in urology.

View Article and Find Full Text PDF

Background: Despite various resources on the subject, there remain questions regarding billing and coding hernia surgery. Recently, social media has been used to disseminate information in about surgery. The purpose of this project is to evaluate posts relating to coding through one online social media platform.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to compare the cost-effectiveness of surgical release to botulinum toxin injections in the treatment of upper-extremity (UE) cerebral palsy (CP).

Methods: A Markov transition-state model was developed to assess the direct and indirect costs as well as accumulated quality-adjusted life-years associated with surgery (surgery group) and continuous botulinum toxin injections (botulinum group) for the treatment of UE CP in children aged 7 to 12 years. Direct medical costs were obtained from institutional billing departments.

View Article and Find Full Text PDF

Billing of botulinum toxin for hyperhidrosis: Ethical considerations.

J Am Acad Dermatol

April 2018

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!